The stock of Kymera Therapeutics Inc (KYMR) has seen a -4.19% decrease in the past week, with a 58.12% gain in the past month, and a 46.41% flourish in the past quarter. The volatility ratio for the week is 4.33%, and the volatility levels for the past 30 days are at 6.26% for KYMR. The simple moving average for the last 20 days is -0.51% for KYMR’s stock, with a simple moving average of 12.74% for the last 200 days.
Is It Worth Investing in Kymera Therapeutics Inc (NASDAQ: KYMR) Right Now?
The 36-month beta value for KYMR is at 2.16. Analysts have varying views on the stock, with 16 analysts rating it as a “buy,” 4 rating it as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for KYMR is 53.16M, and currently, shorts hold a 14.26% of that float. The average trading volume for KYMR on June 26, 2025 was 878.50K shares.
KYMR) stock’s latest price update
Kymera Therapeutics Inc (NASDAQ: KYMR)’s stock price has dropped by -4.25 in relation to previous closing price of 46.47. Nevertheless, the company has seen a loss of -4.19% in its stock price over the last five trading days. zacks.com reported 2025-06-26 that Kymera’s shares drop as Sanofi ends KT-474 development, but Gilead’s oncology deal remains positive.
Analysts’ Opinion of KYMR
Many brokerage firms have already submitted their reports for KYMR stocks, with Morgan Stanley repeating the rating for KYMR by listing it as a “Overweight.” The predicted price for KYMR in the upcoming period, according to Morgan Stanley is $79 based on the research report published on June 03, 2025 of the current year 2025.
B. Riley Securities, on the other hand, stated in their research note that they expect to see KYMR reach a price target of $60. The rating they have provided for KYMR stocks is “Buy” according to the report published on June 03rd, 2025.
BofA Securities gave a rating of “Buy” to KYMR, setting the target price at $51 in the report published on June 02nd of the current year.
KYMR Trading at 22.94% from the 50-Day Moving Average
After a stumble in the market that brought KYMR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -16.47% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at KYMR starting from Ridloff Elena, who sale 4,500 shares at the price of $50.00 back on Jun 11 ’25. After this action, Ridloff Elena now owns 0 shares of Kymera Therapeutics Inc, valued at $225,000 using the latest closing price.
Stock Fundamentals for KYMR
Current profitability levels for the company are sitting at:
- -4.72 for the present operating margin
- 1.0 for the gross margin
The net margin for Kymera Therapeutics Inc stands at -4.09. The total capital return value is set at -0.32. Equity return is now at value -32.17, with -26.97 for asset returns.
Based on Kymera Therapeutics Inc (KYMR), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -2.71. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -1104.09.
Currently, EBITDA for the company is -216.24 million with net debt to EBITDA at 0.02. When we switch over and look at the enterprise to sales, we see a ratio of 50.06. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.49.
Conclusion
In conclusion, Kymera Therapeutics Inc (KYMR) has had a better performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
